Skip to Content
Merck
All Photos(2)

Key Documents

SBR00066

Sigma-Aldrich

Amikacin Ready Made Solution

25 mg/mL in water

Sign Into View Organizational & Contract Pricing


About This Item

CAS Number:
UNSPSC Code:
51281632
NACRES:
NA.76

form

liquid

Quality Level

specific activity

Antibacterial

concentration

25 mg/mL in water

antibiotic activity spectrum

Gram-negative bacteria
Gram-positive bacteria
mycobacteria

Mode of action

protein synthesis | interferes

storage temp.

2-8°C

SMILES string

O=C([C@@H](O)CCN)N[C@H]1[C@H](O[C@@H]2[C@H](O)[C@@H](N)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O[C@@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CN)O3)[C@@H](N)C1.O=S(O)(O)=O.[F,Cl,Br,I]

InChI

1S/C22H43N5O13.H2O4S/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21;1-5(2,3)4/h6-19,21-22,28-35H,1-5,23-26H2,(H,27,36);(H2,1,2,3,4)/t6-,7+,8-,9+,10+,11-,12+,13+,14+,15-,16+,17-,18+,19-,21+,22+;/m0./s1

InChI key

HIBICIOPDUTNRR-XTHCGPPUSA-N

General description

Amikacin is semisynthetic aminoglycoside antibiotic derived from kanamycin A. Amikacin has broad spectrum activity against serious gram-negative bacilli drug resistant infections and also mycobacteria type infections. Amikacin binds to 30S bacterial ribosomal subunit causing a change of conformation, thus disrupting mRNA’s interaction with tRNA and hampering bacterial growth. Amikacin also showed potency against some gram-positive bacteria like methicillin-resistant Staphylococcus aureus (MRSA). Amikacin is extensively used for multidrug resistant tuberculosis treatment with 1ug/mL MIC value against Mycobacterium tuberculosis. Additionally, Amikacin MIC studies of gram negative and gram positive bacteria showed MIC distribution range of 0.094-48µg/ml. Several other studies showed that Amikacin has a synergistic effect combined with β-lactams against methicillin-resistant Staphylococcus spp. strains and Pseudomonas aeruginosa. Amikacin is additionally used for wound healing assays at concentration of 250 µg/mL.

Other Notes

The suggested concentration of Amikacin for assays is 0.094-250 µg/mL therefore, it is recommended to dilute the ready made solution 1:100-266,000. Amikacin:Sulfate ratio 1:1.8

Pictograms

Exclamation mark

Signal Word

Warning

Hazard Statements

Hazard Classifications

Skin Sens. 1

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

S Leitzke et al.
Antimicrobial agents and chemotherapy, 42(2), 459-461 (1998-04-04)
The potential of liposome-encapsulated antibiotics for prolonging drug application intervals was investigated by using a murine model of chronic lethal Mycobacterium avium infection. Liposomal encapsulation of amikacin, but not of ciprofloxacin, resulted in high and sustained drug levels in infected
Etinosa O Igbinosa et al.
TheScientificWorldJournal, 2012, 308034-308034 (2012-05-26)
Pseudomonas aeruginosa is an opportunistic pathogen in environmental waters with a high prevalence of multidrug resistance. In this study the synergistic efficacy of synergy antibiotic combinations in multidrug-resistant P. aeruginosa strains isolated from an abattoir effluent was investigated. Water samples
N Düzgüneş et al.
Antimicrobial agents and chemotherapy, 32(9), 1404-1411 (1988-09-01)
We examined the therapeutic effects of free and liposome-encapsulated amikacin on Mycobacterium avium-M. intracellulare complex infection by using the beige-mouse model of the disease. In the first series of studies, intravenous administration of four weekly doses of 5 mg of
Low-dose amikacin in the treatment of Multidrug-resistant Tuberculosis (MDR-TB)
Sabur, Natasha F., et al
BMC Infectious Diseases, 21, 1-8 (2021)
Yun-Hsin Wang et al.
Toxics, 8(4) (2020-11-26)
(1) Background: Amikacin is an aminoglycoside antibiotic used for treating gram-negative bacterial infections in cancer patients. In this study, our aims are to investigate the migratory inhibition effects of amikacin in human MDA-MB-231 cells. (2) Methods: We used a wound-healing

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service